ly-465608 has been researched along with Hyperlipidemias* in 1 studies
1 other study(ies) available for ly-465608 and Hyperlipidemias
| Article | Year |
|---|---|
Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
The design and synthesis of the dual peroxisome proliferator activated receptor (PPAR) alpha/gamma agonist (S)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-oxazol-4-yl)ethoxy]phenyl]-2-phenoxypropionic acid (2) for the treatment of type 2 diabetes and associated dyslipidemia are described. 2 possesses a potent dual hPPAR alpha/gamma agonist profile (IC(50) = 28 and 10 nM; EC(50) = 9 and 4 nM, respectively, for hPPARalpha and hPPARgamma). In preclinical models, 2 substantially improves insulin sensitivity and potently reverses diabetic hyperglycemia while significantly improving overall lipid homeostasis. Topics: Animals; Binding, Competitive; Cell Line; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Phenylpropionates; Radioligand Assay; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Transcription Factors | 2004 |